Register entry
- Registered sites
- 15
- Active NDC listings
- 80
- Labeller names
- 6
- Live patents
- 0
- Countries
- 7
- Base
- United States
Authorisation
Registered operations
Analytical testing15Active ingredient (API) manufacture9Labelling5Finished drug manufacture8Packaging5
Sites
Registered establishments
15| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Lonza AGRegistrant: Lonza Biologics Inc | Hochbergerstrasse 60 G, Basel, CH-4057, Switzerland (CHE) | Analytical testing | 3014753648480468908 |
| Lonza AGRegistrant: Lonza Biologics Inc | Gebaude 330/331 Schaffhauserstrasse 101, Stein AG, 4332, Switzerland (CHE) | Analytical testing, Finished drug manufacture | 3016502617480533034 |
| Lonza AGRegistrant: Lonza Biologics Inc | Lonzastrasse, Visp, 3930, Switzerland (CHE) | Analytical testing, Active ingredient (API) manufacture | 3002930340480007517 |
| Lonza AGRegistrant: Lonza Biologics Inc | Rottenstrasse 6, Visp, 3930, Switzerland (CHE) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3012793444480436742 |
| Lonza Guangzhou Pharmaceutical Ltd.Registrant: Lonza Biologics Inc | 68, Huangge Dadaobei, Nansha District,, Guangzhou, 511455, China (CHN) | Analytical testing, Active ingredient (API) manufacture | 3006532186545328150 |
| Lonza Biologics Porrino SLRegistrant: Lonza Biologics Inc | La Relba, S/N, O PORRI�O, Pontevedra 36410, Spain (ESP) | Analytical testing, Active ingredient (API) manufacture | 3006067169463612064 |
| Lonza Biologics, plcRegistrant: Lonza Biologics Inc | 228 bath road, Slough, Berkshire SL1 4DX, United Kingdom (GBR) | Analytical testing, Active ingredient (API) manufacture | 1000583959230794810 |
| Lonza Netherlands B.V.Registrant: Lonza Biologics Inc | Urmonderbaan 20 b, Geleen, 6167 RD, Netherlands (NLD) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3014382532492758197 |
| LONZA BIOLOGICS TUAS PTE. LTD.Registrant: Lonza Biologics Inc | 35 Tuas South Avenue 6, Singapore, Singapore 637377, Singapore (SGP) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3009725845936939342 |
| Lonza Bend Inc.Registrant: Lonza Biologics Inc | 64550 Research Rd, Bend, Oregon (OR) 97703, United States (USA) | Analytical testing | 1000656789117222452 |
| Lonza Bend Inc.Registrant: Lonza Biologics Inc | 20503 Builders St, Bend, Oregon (OR) 97701-8507, United States (USA) | Analytical testing, Finished drug manufacture | 3003722743966771631 |
| Lonza Houston, IncRegistrant: Lonza Biologics Inc | 14905 Kirby Dr, Houston, Texas (TX) 77047, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3013629214832903004 |
| Lonza Biologics, Inc.Registrant: Lonza Biologics Inc | 101 International Drive, Building C, Portsmouth, New Hampshire (NH) 03801, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3001451441119479022 |
| Lonza Tampa LLCRegistrant: Lonza Biologics Inc | 5709 JOHNS RD SUITE 1209, TAMPA, Florida (FL) 33634, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3001549109080939373 |
| Lonza Manufacturing LLCRegistrant: Lonza Biologics Inc | 1000 New Horizons Way, Vacaville, California (CA) 95688, United States (USA) | Analytical testing, Active ingredient (API) manufacture | 3032299571119376141 |
Catalogue
Drug listings by form and route
8080 active NDC listings: 46 drug for further processing, 34 bulk ingredient. By marketing category: DRUG FOR FURTHER PROCESSING 46, BULK INGREDIENT 34.
| Dosage form | NDCs |
|---|---|
| liquid | 37 |
| powder | 34 |
| solution | 7 |
| solution, concentrate | 1 |
| suspension | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| lonza ag | 48 |
| lonza biologics, inc. | 21 |
| lonza biologics, plc | 5 |
| lonza biologics inc. | 3 |
| lonza, llc | 2 |
| lonza inc. | 1 |
Catalogue
Marketed products
80| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | AFOXOLANER | powder | 49187-0770BULK INGREDIENT |
| - | Abemaciclib | powder | 49187-0838BULK INGREDIENT |
| - | Apremilast | powder | 49187-0757BULK INGREDIENT |
| - | Asfotase alfa | liquid | 67643-0017DRUG FOR FURTHER PROCESSING |
| - | Avacopan | powder | 49187-0834BULK INGREDIENT |
| - | Bemelanotide | powder | 49187-0759BULK INGREDIENT |
| - | Benzalkonium Chloride | solution, concentrate | 69284-001DRUG FOR FURTHER PROCESSING |
| - | Benzethonium Chloride | powder | 25905-898BULK INGREDIENT |
| - | Benzethonium Chloride | powder | 69284-002BULK INGREDIENT |
| - | Blinatumomab | liquid | 17504-0011DRUG FOR FURTHER PROCESSING |
| - | Brentuximab Vedotin | liquid | 49187-0212DRUG FOR FURTHER PROCESSING |
| - | Brolucizumab | solution | 49187-0226DRUG FOR FURTHER PROCESSING |
| - | Burosumab | liquid | 67643-0036DRUG FOR FURTHER PROCESSING |
| - | Certolizumab pegol | solution | 49187-0228DRUG FOR FURTHER PROCESSING |
| - | EMAPALUMAB 25 mg/ml | liquid | 17504-0012DRUG FOR FURTHER PROCESSING |
| - | Efgartigimod Drug substance | liquid | 67643-0031DRUG FOR FURTHER PROCESSING |
| - | Eftrenonacog alfa | liquid | 67643-0024DRUG FOR FURTHER PROCESSING |
| - | Eslicarbazepin acetate | powder | 49187-0832BULK INGREDIENT |
| - | Firocoxib | powder | 49187-0842BULK INGREDIENT |
| - | Fremanezumab | liquid | 67643-0028DRUG FOR FURTHER PROCESSING |
| - | GABAPENTIN ENACARBIL | powder | 49187-0710BULK INGREDIENT |
| - | ISATUXIMAB | liquid | 67643-0032DRUG FOR FURTHER PROCESSING |
| - | Infliximab 40.0 mg/mL Drug Substance | liquid | 67643-0012DRUG FOR FURTHER PROCESSING |
| - | L-Asparaginase | solution | 49187-0780DRUG FOR FURTHER PROCESSING |
| - | LENALIDOMIDE | powder | 49187-0750BULK INGREDIENT |
| - | LENALIDOMIDE | powder | 49187-0751BULK INGREDIENT |
| - | LISOCABTAGENE MARALEUCEL LENTIVIRUS VECTOR | suspension | 67643-5008DRUG FOR FURTHER PROCESSING |
| - | Lonapegsomatropin-TCGD | solution | 49187-0203DRUG FOR FURTHER PROCESSING |
| - | Lufenuron | powder | 49187-0300BULK INGREDIENT |
| - | Lumateperone tosylate | powder | 49187-0820BULK INGREDIENT |
| - | Lumateperone tosylate non mc | powder | 49187-0821BULK INGREDIENT |
| - | MabY | liquid | 67643-0033DRUG FOR FURTHER PROCESSING |
| - | Macitentan micronized | powder | 49187-0822BULK INGREDIENT |
| - | Macitentan non-micronized | powder | 49187-0823DRUG FOR FURTHER PROCESSING |
| - | Mecasermin | solution | 49187-0810DRUG FOR FURTHER PROCESSING |
| - | Mepolizumab Drug Substance | liquid | 67643-0035DRUG FOR FURTHER PROCESSING |
| - | Miglustat | powder | 49187-0827BULK INGREDIENT |
| - | Momelotinib | powder | 49187-0844BULK INGREDIENT |
| - | NI-0501 6 mg/ml | liquid | 17504-0007DRUG FOR FURTHER PROCESSING |
| - | Obiltoxaximab | liquid | 67643-0018DRUG FOR FURTHER PROCESSING |
| - | Ofatumumab | liquid | 67643-0016DRUG FOR FURTHER PROCESSING |
| - | Olaparib | powder | 49187-0740BULK INGREDIENT |
| - | Olaparib | powder | 49187-0741BULK INGREDIENT |
| - | Osimertinib mesylate | powder | 49187-0846BULK INGREDIENT |
| - | Osimetinib mesylate | powder | 49187-0835BULK INGREDIENT |
| - | PMT Tildipirosin | powder | 49187-0840BULK INGREDIENT |
| - | Polatuzumab vedotin | liquid | 49187-0216DRUG FOR FURTHER PROCESSING |
| - | Rapamycin | powder | 49187-0801BULK INGREDIENT |
| - | Repotrectinib | powder | 49187-0843BULK INGREDIENT |
| - | Rosuvastatin calcium | powder | 49187-0200BULK INGREDIENT |
| - | Rucaparib camsylate | powder | 49187-0815BULK INGREDIENT |
| - | Sacituzumab Govitecan | liquid | 49187-5001DRUG FOR FURTHER PROCESSING |
| - | Sonidegib diphosphate | powder | 49187-0837BULK INGREDIENT |
| - | Tafasitamab | liquid | 67643-0029DRUG FOR FURTHER PROCESSING |
| - | Ticagrelor | powder | 49187-0205BULK INGREDIENT |
| - | Tisotumab vedotin | liquid | 49187-0207DRUG FOR FURTHER PROCESSING |
| - | Tocilizumab | liquid | 67643-7008DRUG FOR FURTHER PROCESSING |
| - | Trastuzumab Emtansine | liquid | 49187-0601DRUG FOR FURTHER PROCESSING |
| - | Trastuzumab/Deruxtecan | liquid | 49187-0224DRUG FOR FURTHER PROCESSING |
| - | Vedolizumab IV | liquid | 67643-0023DRUG FOR FURTHER PROCESSING |
| - | Vedolizumab SC | liquid | 67643-0034DRUG FOR FURTHER PROCESSING |
| - | Voclosporin | powder | 49187-0803BULK INGREDIENT |
| - | Zibotentan (micronized) | powder | 49187-0847BULK INGREDIENT |
| - | efgartigimod | liquid | 17504-0009DRUG FOR FURTHER PROCESSING |
| - | enfortumab vedotin | liquid | 49187-0214DRUG FOR FURTHER PROCESSING |
| - | mPEG-7-OMs 2,5,8,11,14,17,20-Heptaoxadocosan-22-yl methanesulfonate | liquid | 49187-0839BULK INGREDIENT |
| - | mogamulizumab | liquid | 49187-5000DRUG FOR FURTHER PROCESSING |
| - | ocrelizumab | liquid | 67643-7000DRUG FOR FURTHER PROCESSING |
| - | ocrelizumab | liquid | 67643-7001DRUG FOR FURTHER PROCESSING |
| - | pertuzumab | liquid | 67643-7002DRUG FOR FURTHER PROCESSING |
| - | pertuzumab | liquid | 67643-7003DRUG FOR FURTHER PROCESSING |
| - | pertuzumab | liquid | 67643-7004DRUG FOR FURTHER PROCESSING |
| - | rADA (Deaminase, adenosine) | solution | 49187-0785DRUG FOR FURTHER PROCESSING |
| - | rituximab | liquid | 67643-7005DRUG FOR FURTHER PROCESSING |
| - | rituximab | liquid | 67643-7006DRUG FOR FURTHER PROCESSING |
| - | tisotumab | liquid | 17504-0008DRUG FOR FURTHER PROCESSING |
| - | tividenofusp alfa-eknm | solution | 49187-5002DRUG FOR FURTHER PROCESSING |
| - | tocilizumab | liquid | 67643-7007DRUG FOR FURTHER PROCESSING |
| - | vandetanib | powder | 49187-0220BULK INGREDIENT |
| - | vandetanib non-mc | powder | 49187-0221BULK INGREDIENT |
Neighbours
Registered in the same town
12- Merck & Co., Inc.Singapore, SGP · 5 sites
- PETNET Solutions, Inc.HOUSTON, TX; TAMPA, FL · 2 sites
- Cardinal Health 418, Inc.Houston, TX; Tampa, FL · 2 sites
- Novartis Pharmaceuticals CorporationBasel, CHE; Singapore, SGP · 2 sites
- SanofiSingapore, SGP · 2 sites
- Genentech, Inc.Basel, CHE; Singapore, SGP · 2 sites
- The University of Texas MD Anderson Cancer CenterHouston, TX · 2 sites
- ten23 health Valais AGVisp, CHE · 2 sites
- Baxalta US Inc.Singapore, SGP
- Charles River Laboratories, Inc.Singapore, SGP
- Oxarc LLCBend, OR
- AbbVie Inc.Singapore, SGP
Compare
Comparable companies in United States
- AstraZeneca PLC15 sites · 153 NDC
- Oxarc LLC15 sites · 5 NDC
- Charles River Laboratories, Inc.15 sites · 0 NDC
- Baxter Healthcare Corporation16 sites · 416 NDC
- AbbVie Inc.13 sites · 131 NDC
- Sigma-Aldrich Corporation13 sites · 25 NDC
- Siegfried USA, LLC12 sites · 54 NDC
- SOFIE Co. dba SOFIE12 sites · 5 NDC
- The Procter & Gamble Manufacturing Company11 sites · 849 NDC
- Patheon Manufacturing Services LLC19 sites · 319 NDC
Enquiry
Common questions
- Is Lonza Biologics Inc FDA approved?
- Lonza Biologics Inc holds 15 FDA-registered establishments across 7 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Lonza Biologics Inc's drugs manufactured?
- At registered sites in Switzerland, China, Spain, the United Kingdom, the Netherlands, Singapore and 1 other countries. The FDA register lists Basel; Stein AG; Visp; Guangzhou; O PORRI�O; Slough, and 7 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.
- What drugs does Lonza Biologics Inc make?
- 80 products are listed under Lonza Biologics Inc in the openFDA NDC Directory, most often as liquid; powder; solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.